Inhibition of VEGF signal transduction

Advances in Experimental Medicine and Biology

Volumn 476, Issue , 2000, Pages 307-310

  Wedge, S R ^a   Ogilvie, D J ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

N (4 BROMO 2 FLUOROPHENYL) 6 METHOXY 7 [2 (1H 1,2,3 TRIAZOL 1 YL)ETHOXY] 4 QUINAZOLINAMINE; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR;

CANCER INHIBITION; CONFERENCE PAPER; ENZYME ACTIVITY; GROWTH INHIBITION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SOLID TUMOR;

EID: 0034471773     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-4221-6_25     Document Type: Conference Paper

References (6)

1. Production of the angiogenic factors VEGF and bFGF at tumour sites may also confer an acute haemodynamic advantage to the tumour
2. Angiogenesis in cancer, vascular, rheumatoid and other disease
3. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo
4. Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanised monoclonal antibody
5. Vascular permeability factor (VPF, VEGF) in tumor biology
6. Effect of the VEGF receptor tyrosine kinase inhibitor ZD4190 on vascular endothelial permeability